AMCP 2024 Conference to Feature New Outcomes Research from Analysis Group

April 11, 2024

Analysis Group’s HEOR, Epidemiology & Market Access practice will present 13 posters, including platinum and silver awardees and two Encore presentations, at the Academy of Managed Care Pharmacy’s (AMCP’s) 2024 Meeting, which will be held from April 15 to 18, 2024, in New Orleans, LA.

Platinum Ribbon (Podium Presentation)

Silver Ribbon

  • “Identification of high-grade cytokine release syndrome in retrospective databases,” coauthored by an Analysis Group team – including Vice President Marie-Hélène Lafeuille, Manager Philippe Thompson-Leduc, Associate Aditi Shah, Senior Research Professional Anabelle Tardif-Samson, and Research Professional Bronwyn Moore – in collaboration with researchers from Yale School of Medicine and Johnson & Johnson.

Additional poster presentations include:

  • “Budget impact analysis of fam-trastuzumab deruxtecan-nxki (T-DXd) for the treatment of unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low breast cancer in the United States,” coauthored by an Analysis Group team – including Vice President Jinlin Song, Manager Chelsey Yang, and Senior Analyst Churong Xu – in collaboration with researchers from Daiichi Sankyo and AstraZeneca.
  • “Budget Impact Analysis of nadofaragene firadenovec (Adstiladrin) for the treatment of high-grade, Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer in the United States,” coauthored by an Analysis Group team – including Vice President Min Yang, Manager Xinglei Chai, Associate Dongni Ye, and Senior Analyst Angela Zhao – in collaboration with researchers from Ferring and The University of Texas Southwestern Medical Center.
  • “Cost-per-outcome analysis of nivolumab plus relatlimab vs BRAF/MEK inhibitor combinations for first-line treatment of patients with BRAF-mutant advanced melanoma,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou and Associate Fan Yang – in collaboration with researchers from Minnesota Oncology and Bristol Myers Squibb.
  • “Economic burden of patients with primary biliary cholangitis by line of therapy in the United States,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Manager Su Zhang, and Senior Analyst Shravanthi Seshasayee – in collaboration with researchers from Ipsen, Weill Cornell Medical College, and Washington State University.
  • “Health care costs and unmet needs among patients treated for EGFR-mutated advanced or metastatic non-small cell lung cancer,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice Presidents Bruno Émond and Marie-Hélène Lafeuille, Manager Laura Morrison, and Senior Research Professionals Annalise Hilts and Samuel Schwartzbein – in collaboration with researchers from Johnson & Johnson and Oncology Hematology Care.
  • “Health care resource use and costs for metastatic prostate cancer before and after progression to castration resistance,” coauthored by an Analysis Group team – including Vice Presidents Rajeev Ayyagari and Viviana García-Horton and Associates Yuehan Zhang and Annika Anderson – in collaboration with researchers from Bayer and the Carolina Urologic Research Center.
  • “Health care resource utilization, costs, and steroid use among patients with chronic rhinosinusitis with nasal polyposis treated with mepolizumab: A real-world claims analysis,” coauthored by an Analysis Group team – including Principal François Laliberté, Senior Research Professional Annalise Hilts, Research Professional Kaixin Zhang, and Associate Ramya Ramasubramanian – in collaboration with researchers from GSK.
  • “Health care resource utilization and financial burden of adverse events with current first-line therapies among patients with HER2-negative metastatic gastric or gastroesophageal junction cancers in the United States,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Manager Wei Song, Associate Travis Wang, and Senior Analyst Adina Zhang – in collaboration with researchers from Astellas and the Moffitt Cancer Center.
  • “Real-world treatment patterns and health care resource utilization (HCRU) in patients (pts) with advanced/metastatic non–small cell lung cancer (a/mNSCLC) who have successfully completed first-line (1L) therapy,” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Managers Ella X. Du and Mandy Du, and Senior Analyst Hong Wang – in collaboration with researchers from GSK, Boston University Chobanian & Avedisian School of Medicine, and Boston Medical Center.

Encore presentations:

  • “Assessing risdiplam utilization, adherence, and associated health care costs in patients with spinal muscular atrophy: Analysis of a US retrospective claims database,” coauthored by an Analysis Group team – including Vice President Min Yang, Manager Wei Song, Associate Raj Desai, and Senior Analyst Mingchen Ye – in collaboration with researchers from Novartis.
  • “Modeling long-term outcomes for patients with immunoglobulin A nephropathy from short-term proteinuria data,” coauthored by Vice President Jenny Zhou and researchers from Travere Therapeutics and the University of Washington School of Pharmacy.

Read more about AMCP 2024